June 26, 2008 Mumbai, India: Lupin Ltd, announced today that
Dr. Raj Kamboj has joined the company as President - New Chemical Entity Research. This reflects the Company's commitment to continually strengthen its team by attracting the best talent globally.
Raj is an eminent scientist from the world of drug discovery. He is a PhD from University of Adelaide, Australia & joins Lupin from Xenon Pharmaceuticals Inc., Vancouver, where he had been working for the past 5 years. He has returned to India after 26 years and brings with him a wide range of experience in the field of Drug Discovery & Clinical development. Prior to Xenon, he was working with Allelix, Canada. In both companies Raj was instrumental in taking the companies from the inception of the drug discovery group all the way to multiple licensing transactions and collaborations.
"We are very excited to have Raj join us as the Chief of our drug discovery program", Dr. D B Gupta, Chairman, Lupin Ltd. said.
"He brings with him a vast pool of knowledge and experience which will be a great value add for Lupin's
Lupin is committed to developing new and innovative healthcare products focusing on unmet needs. It has a pipeline of four Investigational New Drugs that focus on three different disease areas namely Migraine, Psoriasis and Tuberculosis. The Company also has pre-clinical programs in Diabetes and Rheumatoid Arthritis.
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.
The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardio-vasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.
Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.
For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27, 730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million) respectively.
For further information please contact:
Head, Corporate Communications
022 66402323 Extn: 2531
Fax: 022 66402534